Uncategorized
Cellular Dynamics International launches Opsis Therapeutics to develop retinal disease treatments
Cellular Dynamics International has launched Opsis Therapeutics, a new project aimed at discovering and developing medicines for patients with retinal diseases, according to a company press release.CDI, which develops and manufactures induced pluripotent stem cell (iPSC) products, formed Opsis Therapeutics to focus on researching and manufacturing new retinal disease treatments with a “cross-disciplinary team of internationally recognized advisors and development partners,” the release said. These partners have experience in iPSC manufacture, iPSC differentiation into retinal lineages, retinal cell biology, preclinical modeling of retinal disease and subretinal surgery.